Cipla was trading higher by 3% to Rs 596 on the BSE in early morning trade after the drug maker on Wednesday said that it has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Indore facility
Cipla Limited on Wednesday announced that it has received Establishment Inspection Report (EIR) from the US FDA for its Indore facility indicating formal closure of the US FDA inspection conducted in July/August, 2015.The FDA had made adverse
Cipla has dipped 6.5% to Rs 562 on the BSE, its sharpest intra-day fall in past three months, on media reports that the United States Food and Drug Administration (USFDA) inspected the company’s Goa facility.
Drug companies are facing a tough environment due to the government bringing more products under the price control policy and tightening of registration procedure that has impacted time to market newer products, Cipla Chairman YK Hamied has said.
Cipla has surged 5% to Rs 544 on the National Stock Exchange (NSE) after the company announced an improvement of around 200 basis points in base business EBITDA (earnings before interest, depreciation and taxes) margin.
An employee works at the reception area of Cipla at its headquarters in MumbaiCipla is investing 1.3 billion South African rand (about Rs 600 crore ) in a biotechnology plant in South Africa as it aims to make cancer drugs affordable and grow presence in
Cipla surprised the market with a sharp drop of 69% in its quarterly net profit, much below the expectations of analysts. The stock touched a new 52-week low, falling over 7% but recovered some ground later in the day.
Cipla has dipped 7% to Rs 460, also its 52-week low on the BSE, after the company reported a sharp 69% year-on-year drop in net profit to Rs 81 crore in the quarter ended March 2016 (Q4FY16), on account of one-off expenses related to inventory reduction
Drug maker Cipla’s net profit fell 68.9 per cent year-on-year (y-o-y) to Rs 81 crore in the quarter ended March 2016, on account of one-off expenses related to inventory reduction and closure of business in some small-sized foreign markets.